Table 1 Baseline characteristics of participants
Variables | LAT/SEC group (n = 87) | Non-LAT/SEC group (n = 1071) | P |
|---|---|---|---|
Age (years) | 61.47 ± 10.78 | 56.54 ± 12.30 | <0.001* |
Female, n (%) | 38 (43.68) | 351 (32.77) | 0.045* |
Non-paroxysmal AF, n (%) | 38 (43.68) | 175 (16.34) | <0.001* |
Type 2 diabetes mellitus, n (%) | 31 (36.63) | 148 (13.82) | <0.001* |
Hypertension, n (%) | 61 (70.11) | 455 (42.48) | <0.001* |
Stroke/TIA, n (%) | 9 (10.34%) | 19 (1.77) | <0.001* |
Heart failure, n (%) | 27 (31.03) | 129 (12.04) | <0.001* |
Vascular disease, N (%) | 17 (19.54) | 71 (6.63) | <0.001* |
COPD, N (%) | 21 (18.27) | 211 (19.70) | 0.855 |
Age ≥65, N (%) | 38 (43.68) | 310 (28.94) | 0.005* |
Age ≥75, N (%) | 6 (6.90) | 46 (4.30) | 0.275 |
LVDd, (mm) | 46.79 ± 4.67 | 45.84 ± 4.54 | 0.070 |
LAd, (mm) | 41.36 ± 5.58 | 36.29 ± 5.66 | <0.001* |
LVEF, (%) | 63.86 ± 6.89 | 65.79 ± 7.02 | 0.014* |
Uric acid, (μmol/L) | 395.98 ± 99.68 | 356.49 ± 78.04 | <0.001* |
Hb1Ac, (%) | 6.13 ± 0.41 | 5.89 ± 0.45 | <0.001* |
LDL-C, (μmol/L) | 3.06 ± 0.93 | 2.90 ± 0.81 | 0.336 |
D-dimer, (μg/L) | 220.45 ± 210.42 | 247.87 ± 439.71 | 0.412 |
CHADS2 score | 1.64 ± 1.27 | 0.76 ± 0.66 | <0.001* |
CHA2DS2-VASc score | 2.71 ± 1.68 | 1.45 ± 1.30 | <0.001* |